Research and Publications
Research Interests
Dr. Chovatiya’s research focus includes the intersection of cutaneous immunology and inflammatory disease. He has a particular interest in optimizing patient-centered care, understanding chronic disease burden especially in understudied inflammatory diseases, and improving care across diverse skin types. His research efforts include publications in the areas of:
-Clinical trials
-Patient-reported outcomes
-Health services research
-Epidemiology
-Implementation science
-Health and Social Disparities
-Translational therapy
-Immunology
-And much more
Research Abstracts (selected)
- Alexis AF, Kircik L, Chovatiya R, Rice ZP, Bhutani T, Brown PM, Piscitelli SC, Rubenstein DS, Tallman AM, Armstrong AW. Tapinarof Cream 1% Once Daily is Efficacious for the Treatment of Moderate to Severe Atopic Dermatitis in Patients with Skin of Color Down to 2 Years of Age in Two Pivotal Phase 3 Trials. Poster presentation. Fall Clinical Dermatology Conference for PAs and NPs, Scottsdale, AZ. May 31-June 2, 2024.
- Alexis AF, Kircik L, Chovatiya R, Rice ZP, Bhutani T, Brown PM, Piscitelli SC, Rubenstein DS, Tallman AM, Armstrong AW. Tapinarof Cream 1% Once Daily is Efficacious for the Treatment of Moderate to Severe Atopic Dermatitis in Patients with Skin of Color Down to 2 Years of Age in Two Pivotal Phase 3 Trials. Poster presentation. Congress of Clinical Dermatology, Amelia Island, FL. May 30-June 2, 2024.
- Ingram J, Porter M, Chovatiya R, Giamarellos-Bourboulis EJ, Bechara FG, Fujita H, Gulliver W, Muller E, Bari M, Rolleri R, Byerly R, Kirby JS. Bimekizumab response maintenance to 48 weeks in patients with moderate to severe hidradenitis suppurativa: Pooled responder analysis from the phase 3, double-blind, placebo-controlled, randomised clinical trials BE HEARD I and II. Poster Presentation. SIDEMAST 2024, Naxos, Italy. May 28-31, 2024.
- Bunick CG, Chovatiya R, Guttman E, Shahriari M, Boguniewicz M, Gao X, Greiwe J, Blauvelt A, Irvine AD, Levy GF, Platt A, Dilley D, Teixeira H, Altman K, Grada A, Silverberg JI. Long-Term 5-Year Safety of Upadacitinib in Moderate-To-Severe Atopic Dermatitis: An Integrated Analysis With Over 7000 Patient-Years of Exposure. Poster Presentation. SIDEMAST 2024, Naxos, Italy. May 28-31, 2024.
- Simpson E, Biedermann T, Kircik L, Chovatiya R, Figueras I, Casillas M, Gallo G, Ding Y, Xu C, Pierce E, Agell H, Vestergaard C. Raising the bar of efficacy in atopic dermatitis: depth of response in patients treated with lebrikizumab over 52 weeks. Poster Presentation. Taiwan Dermatology Aesthetics Conference, Taipei, Taiwan. May 24-26, 2024.
- Zirwas M, Chovatiya R, DuBois J, Guttman E, Laquer V, Lee M, Moore A, Raoof J, Zhanel G, Seal M, Meng X, Burnett P, Chu D, Berk D, Kato S. Antifungal Effects on Malassezia Species in an Open-Label, Phase 1, Maximal Use Study of Roflumilast Foam 0.3% in Patients With Seborrheic Dermatitis. Poster presentation. Society for Investigative Dermatology Annual Meeting, Dallas, TX. May 15-18, 2023.
- Polaskey MT, Chang CH, Daftary K, Fakhraie S, Miller C, Chovatiya R. Prevalence of seborrheic dermatitis: a systematic review and meta-analysis. Poster presentation. Society for Investigative Dermatology Annual Meeting, Dallas, TX. May 15-18, 2023.
- Chang CH, Hanna E, Polaskey MT, Nunes D, Kim J, Chovatiya R. Prevalence and association of psoriasis with seborrheic dermatitis: A systematic review and meta-analysis. Poster presentation. Society for Investigative Dermatology Annual Meeting, Dallas, TX. May 15-18, 2023.
- Polaskey MT, Chovatiya R. Describing atopic dermatitis in the real world: A retrospective health system analysis. Oral presentation (Concurrent Mini-Symposium: Clinical Research – Socio-behavioral and Health/Quality of Life Services Research). Society for Investigative Dermatology Annual Meeting, Dallas, TX. May 15-18, 2023.
- Chang CH, Hanna E, Polaskey MT, Nunes D, Kim J, Chovatiya R. Prevalence and association of psoriasis with seborrheic dermatitis: A systematic review and meta-analysis. Oral presentation. IPC Symposium at SID 2024: Advances in Technologies and Analytics in Understanding Psoriasis Pathophysiology, Dallas, TX. May 15, 2023.
- Murase J, Chovatiya R, Strowd L, Thyssen J, Bangert C, Atwater A, Gallo G, Bardolet L, Yang F Zhong J, Staumont-Sallé D. Lebrikizumab Improved and Cleared Facial and Hand Dermatitis in Patients With Moderate-to-Severe Atopic Dermatitis. Poster presentation. Australasian College of Dermatologists Annual Scientific Meeting, Perth, Australia. May 11-13, 2024.
- Silverberg J, Bieber T, Paller A, Beck L, Kamata M, Puig L, Wiseman M, Ezzedine K, Foley P, Johansson E, Dossenbach M, Akmaz B, Casillas M, Karlsson A, Chovatiya R. Efficacy comparison of targeted systemic monotherapies including lebrikizumab for moderate-to-severe atopic dermatitis: a network meta-analysis. Poster presentation. Australasian College of Dermatologists Annual Scientific Meeting, Perth, Australia. May 11-13, 2024.
- Alexis AF, Kircik L, Chovatiya R, Rice ZP, Bhutani T, Brown PM, Piscitelli SC, Rubenstein DS, Tallman AM, Armstrong AW. Tapinarof Cream 1% Once Daily is Efficacious for the Treatment of Moderate to Severe Atopic Dermatitis in Patients with Skin of Color Down to 2 Years of Age in Two Pivotal Phase 3 Trials. Poster presentation. AMCP Annual Meeting, New Orleans, LA. April 15-18, 2024.
- Chovatiya R, Guttman E, Ungar B, Hanna D, Seal MS, Taylor CK, Stephenson B, Burnett P. Survey of healthcare providers to understand the diagnosis and treatment patterns for patients with seborrheic dermatitis. Poster presentation. AMCP Annual Meeting, New Orleans, LA. April 15-18, 2024.
- Chaudhry S, Sadick N, Silverberg J, Chovatiya R, Reich A, Szepietowski JC, Baran W, Arasiewicz H, Owczarczyk-Saczonek A, Kwiek B, Gooderham M, Bissonnette R, Lee Z, Xu H, Liu Y, Mellskog K, Lewis B, Jue C, Fanton C, Kotzin B, Tagliaferri M, Zalevsky J, Rosmarin D. A Phase 2b, Randomized, Double-Blinded, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in Adults with Severe to Very-Severe Alopecia Areata (Rezolve AA). Oral presentation. 13th Annual World Congress for Hair Research, Dallas, TX. April 6-9, 2024.
- Jang YH, Zirwas M, Chovatiya R, Stein Gold L, Shumel B, Praestgaard A, Chen Z, Gonzalez T, Gherardi G, Lawless E. Conjunctivitis adverse events in dupilumab clinical trials. Poster presentation. Korean Society of Investigative Dermatology, Seoul, Korea. Virtual Meeting. March 22-23, 2024.
- Chovatiya R, Fakhraie S, Daftary K, Cella D. Validation and Feasibility of Patient-Reported Outcomes Information System Computer Adaptive Tests for Anxiety and Depression in Atopic Dermatitis: A Real-World Practice-Based Study. Poster presentation (oral poster). American Academy of Dermatology Annual Meeting, San Diego, CA. March 8-12, 2024.
- Chovatiya R, Fakhraie S, Daftary K, Cella D. Validation and Feasibility of Patient-Reported Outcomes Information System Computer Adaptive Tests for Sleep Disturbance and Sleep-Related Impairment in Atopic Dermatitis: A Real-World Practice-Based Study. Poster presentation. American Academy of Dermatology Annual Meeting, San Diego, CA. March 8-12, 2024.
- Chovatiya R, Fakhraie S, Daftary K. A Prospective Study of Tralokinumab in Atopic Dermatitis Patients with Inadequate Response to Dupilumab. Poster presentation (oral poster). American Academy of Dermatology Annual Meeting, San Diego, CA. March 8-12, 2024.
- Polaskey MT, Chovatiya R. Assessing the Approach to Description of Cutaneous Manifestations Associated with Atopic Dermatitis in Real-World Clinical Practice. Poster presentation. American Academy of Dermatology Annual Meeting, San Diego, CA. March 8-12, 2024.
- Polaskey MT, Chovatiya R. Assessing the Real-World Approach to Description of Patient Burden Associated with Atopic Dermatitis in Clinical Practice Poster presentation. American Academy of Dermatology Annual Meeting, San Diego, CA. March 8-12, 2024.
- Polaskey MT, Chovatiya R. Assessing the Real-World Approach to Description of Longitudinal Course and Treatment Response Associated with Atopic Dermatitis in Clinical Practice. Poster presentation. American Academy of Dermatology Annual Meeting, San Diego, CA. March 8-12, 2024.
- Alexis AF, Kircik L, Chovatiya R, Rice ZP, Bhutani T, Brown PM, Piscitelli SC, Rubenstein DS, Tallman AM, Armstrong AW. Tapinarof Cream 1% Once Daily is Efficacious for the Treatment of Moderate to Severe Atopic Dermatitis in Patients with Skin of Color Down to 2 Years of Age in Two Pivotal Phase 3 Trials. Poster presentation. American Academy of Dermatology Annual Meeting, San Diego, CA. March 8-12, 2024.
- Yosipovitch G, Lio P, Legat FJ, Deleuran M, Chovatiya R, Pierce E, Casillas M, Ding Y, Yang FE, Bardolet L, Ständer S. Improvement of Itch and Sleep Disturbance Symptoms in Patients With Moderate-to-Severe Atopic Dermatitis Treated With Lebrikizumab Is Maintained Over 52 Weeks as Measured Weekly With POEM. Poster presentation. American Academy of Dermatology Annual Meeting, San Diego, CA. March 8-12, 2024.
- Alexis A, Chovatiya R, Taylor S, Elbuluk N, Kindred C, Hansen M, Atwater AR, Rueda MJ, Becker TB, Shi V. Shifting the care paradigm for individuals with skin of color (SOC) in the United States (US): A comprehensive review of care gaps and emerging initiatives in dermatology. Poster presentation. Skin of Color Society Scientific Symposium, San Diego, CA. March 7, 2024.
- Augustyniak M, Lazure P, Chovatiya R, Fishbein A, Lewis MO, Folstein S, May J, Murray S. “A New Horizon of Atopic Dermatitis Therapy – Program Assessment and Evaluation Results.” J Allergy Clin Immunol. 153(2):AB127. Poster Presentation. American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting, Washington, DC. February 23-26, 2024. https://doi.org/10.1016/j.jaci.2023.11.420.
- Ingram J, Porter M, Chovatiya R, Giamarellos-Bourboulis EJ, Bechara FG, Fujita H, Gulliver W, Muller E, Bari M, Rolleri R, Byerly R, Kirby JS. Bimekizumab response maintenance to 48 weeks in patients with moderate to severe hidradenitis suppurativa: Pooled responder analysis from the phase 3, double-blind, placebo-controlled, randomised clinical trials BE HEARD I and II. Poster Presentation. Masterclasses in Dermatology, San Juan, Puerto Rico. February 16-19, 2024.
- Ingram J, Porter M, Chovatiya R, Giamarellos-Bourboulis EJ, Bechara FG, Fujita H, Gulliver W, Muller E, Bari M, Rolleri R, Byerly R, Kirby JS. Bimekizumab response maintenance to 48 weeks in patients with moderate to severe hidradenitis suppurativa: Pooled responder analysis from the phase 3, double-blind, placebo-controlled, randomised clinical trials BE HEARD I and II. Poster Presentation. Winter Clinical Dermatology Conference Miami, Miami, FL. February 16-19, 2024.
- Chovatiya R, Sawad AB, Fournier J, Fountain D, Shaw C, Toomey J, Vazquez M, Tallman AM, Fredericks D. Efficacy Outcomes in Clinical Trials of Atopic Dermatitis Treatments: A Systematic Literature Review. Poster Presentation. Winter Clinical Dermatology Conference Miami, Miami, FL. February 16-19, 2024.
- Murase J, Chovatiya R, Strowd L, Thyssen J, Bangert C, Atwater A, Gallo G, Bardolet L, Yang F Zhong J, Staumont-Sallé D. Lebrikizumab Improved and Cleared Facial and Hand Dermatitis in Patients With Moderate-to-Severe Atopic Dermatitis. Poster presentation. 18th JeddaDerm Conference, Jeddah, Saudi Arabia. February 14-17, 2024.
- Bunick CG, Chovatiya R, Guttman E, Shahriari M, Boguniewicz M, Gao X, Greiwe J, Blauvelt A, Irvine AD, Levy GF, Platt A, Dilley D, Teixeira H, Altman K, Grada A, Silverberg JI. Long-Term 5-Year Safety of Upadacitinib in Moderate-To-Severe Atopic Dermatitis: An Integrated Analysis With Over 7000 Patient-Years of Exposure. Poster Presentation. Maui Derm Hawaii, Maui, HI. January 22-26.
- Ingram J, Porter M, Chovatiya R, Giamarellos-Bourboulis EJ, Bechara FG, Fujita H, Gulliver W, Muller E, Bari M, Rolleri R, Byerly R, Kirby JS. Bimekizumab response maintenance to 48 weeks in patients with moderate to severe hidradenitis suppurativa: Pooled responder analysis from the phase 3, double-blind, placebo-controlled, randomised clinical trials BE HEARD I and II. Oral presentation (Late-Breaking Research). Maui Derm Hawaii, Maui, HI. January 22-26, 2024.
- Bunick CG, Chovatiya R, Guttman E, Shahriari M, Boguniewicz M, Gao X, Greiwe J, Blauvelt A, Irvine AD, Levy GF, Platt A, Dilley D, Teixeira H, Altman K, Grada A, Silverberg JI. Long-Term 5-Year Safety of Upadacitinib in Moderate-To-Severe Atopic Dermatitis: An Integrated Analysis With Over 7000 Patient-Years of Exposure. Poster Presentation. Winter Clinical Dermatology Conference Hawaii, Honolulu, HI. January 12-17, 2024.
- Ingram J, Porter M, Chovatiya R, Giamarellos-Bourboulis EJ, Bechara FG, Fujita H, Gulliver W, Muller E, Bari M, Rolleri R, Byerly R, Kirby JS. Bimekizumab response maintenance to 48 weeks in patients with moderate to severe hidradenitis suppurativa: Pooled responder analysis from the phase 3, double-blind, placebo-controlled, randomised clinical trials BE HEARD I and II. Poster Presentation. Winter Clinical Dermatology Conference Hawaii, Honolulu, HI. January 12-17, 2024.
- Simpson E, Biedermann T, Kircik L, Chovatiya R, Figueras I, Casillas M, Gallo G, Ding Y, Xu C, Pierce P, Agell H, Vestergaard C. Raising the bar of efficacy in atopic dermatitis: depth of response in patients treated with lebrikizumab over 52 weeks. Poster Presentation. Winter Clinical Dermatology Conference Hawaii, Honolulu, HI. January 12-17, 2024.
- Silverberg J, Bieber T, Paller A, Beck L, Kamata M, Puig L, Wiseman M, Ezzedine K, Foley P, Johansson E, Dossenbach M, Akmaz B, Casillas M, Karlsson A, Chovatiya R. Efficacy comparison of targeted systemic monotherapies including lebrikizumab for moderate-to-severe atopic dermatitis: a network meta-analysis. Poster Presentation. Winter Clinical Dermatology Conference Hawaii, Honolulu, HI. January 12-17, 2024.
- Zirwas M, Chovatiya R, Stein Gold L, Shumel B, Praestgaard A, Chen Z, Gonzalez T, Gherardi G, Lawless E. Conjunctivitis adverse events in dupilumab clinical trials. Oral presentation (Late-Breaking Research). Revolutionizing Atopic Dermatitis Conference, Virtual Meeting. December 10, 2023.
- Alexis A, Jones MA, Chovatiya R, Flohr C, Irvine A, AlMurrawi M, Atwater A, Ding Y, Qiao M, Pierce E, Pau-Charles I, Heath C. Lebrikizumab demonstrates significant efficacy versus placebo across race and ethnicity subgroups in patients with moderate-to-severe atopic dermatitis. Oral presentation (Late-Breaking Research). Revolutionizing Atopic Dermatitis Conference, Virtual Meeting. December 10, 2023.
- Bunick CG, Chovatiya R, Guttman E, Shahriari M, Boguniewicz M, Gao X, Greiwe J, Blauvelt A, Irvine AD, Levy GF, Platt A, Dilley D, Teixeira H, Altman K, Grada A, Silverberg JI. Long-Term 5-Year Safety of Upadacitinib in Moderate-To-Severe Atopic Dermatitis: An Integrated Analysis With Over 7000 Patient-Years of Exposure. Oral presentation (Late-Breaking Research). Revolutionizing Atopic Dermatitis Conference, Virtual Meeting. December 10, 2023.
- Chovatiya R, Wollenberg A, Ribero S, Saeki H, Øland CB, Steffensen LA, Tindberg AM, Thyssen JP, Blauvelt A. Improvement of the head and neck regions with continuous tralokinumab treatment for up to 4 years in adults with moderate-to-severe atopic dermatitis. Poster presentation. Revolutionizing Atopic Dermatitis Conference, Virtual Meeting. December 10, 2023.
- Murase J, Chovatiya R, Strowd L, Thyssen J, Bangert C, Atwater A, Gallo G, Bardolet L, Yang F Zhong J, Staumont-Sallé D. Lebrikizumab Improved and Cleared Facial and Hand Dermatitis in Patients With Moderate-to-Severe Atopic Dermatitis. Poster presentation. Revolutionizing Atopic Dermatitis Conference, Virtual Meeting. December 10, 2023.
- Chovatiya R, Chao J, Chuang C, Yang M, Shumel B, Martins B, Bego-Le-Bagousse G, Sierka D, Delevry D. Dupilumab improves disease control and patient-reported outcomes in adults with atopic dermatitis in clinical practice: Subgroup analysis of Black/African American population from RELIEVE-AD. Poster Presentation. Fall Clinical Dermatology Conference, Las Vegas, NV. October 19-22, 2023.
- Chovatiya R, Chao J, Chuang C, Yang M, Shumel B, Martins B, Bego-Le-Bagousse G, Sierka D, Delevry D. Dupilumab decreases concomitant therapy use in adults with atopic dermatitis in clinical practice: Subgroup analysis of Black/African American population from RELIEVE-AD. Poster Presentation. Fall Clinical Dermatology Conference, Las Vegas, NV. October 19-22, 2023.
- Delevry D, Chao J, Chuang C, Yang M, Shumel B, Martins B, Bego-Le-Bagousse G, Sierka D, Chovatiya R. Dupilumab improves treatment satisfaction and health-related quality of life in adults with atopic dermatitis in clinical practice: Subgroup analysis of Black/African American population from RELIEVE-AD. Poster Presentation. Fall Clinical Dermatology Conference, Las Vegas, NV. October 19-22, 2023.
- Chovatiya R, Wollenberg A, Ribero S, Saeki H, Øland CB, Steffensen LA, Tindberg AM, Thyssen JP, Blauvelt A. Improvement of the head and neck regions with continuous tralokinumab treatment for up to 4 years in adults with moderate-to-severe atopic dermatitis. Poster Presentation. Fall Clinical Dermatology Conference, Las Vegas, NV. October 19-22, 2023.
- Silverberg J, Bieber T, Paller A, Beck L, Kamata M, Puig L, Wiseman M, Ezzedine K, Foley P, Johansson E, Dossenbach M, Akmaz B, Casillas M, Karlsson A, Chovatiya R. Efficacy comparison of targeted systemic monotherapies including lebrikizumab for moderate-to-severe atopic dermatitis: a network meta-analysis. Poster Presentation. Fall Clinical Dermatology Conference, Las Vegas, NV. October 19-22, 2023.
- Murase J, Chovatiya R, Strowd L, Thyssen J, Bangert C, Atwater A, Gallo G, Bardolet L, Yang F Zhong J, Staumont-Sallé D. Lebrikizumab Improved and Cleared Facial and Hand Dermatitis in Patients With Moderate-to-Severe Atopic Dermatitis. Poster presentation. Fall Clinical Dermatology Conference, Las Vegas, NV. October 19-22, 2023.
- Simpson E, Biedermann T, Kircik L, Chovatiya R, Figueras I, Casillas M, Gallo G, Ding Y, Xu C, Pierce P, Agell H, Vestergaard C. Raising the bar of efficacy in atopic dermatitis: depth of response in patients treated with lebrikizumab over 52 weeks. Poster presentation. Fall Clinical Dermatology Conference, Las Vegas, NV. October 19-22, 2023.
- Chovatiya R, Guttman E, Ungar B, Hanna D, Seal MS, Taylor CK, Stephenson B, Burnett P. Survey of healthcare providers to understand the diagnosis and treatment patterns for patients with seborrheic dermatitis. Poster presentation. AMCP Nexus 2023, Orlando, FL. October 16-19, 2023.
- Mayo T, Chovatiya R, Shi V, Naik HB, Benhadou F, Costanzo A, Davis L, Lambert J, Rolleri R, Zouboulis CC. Bimekizumab in Black/African-American Patients with Moderate to Severe Hidradenitis Suppurativa in BE HEARD I & II. Poster Presentation. Symposium on Hidradenitis Suppurativa Advances (SHSA), Phoenix, AZ. October 13-15, 2023.
- Silverberg J, Rosmarin D, Chovatiya R, Schleicher S, Kircik L, Rodgers T, Chaudhry S, Fanton C, Yu D, Liu Y, Kotzin B, Tagliaferri M, Zalevsky J. Efficacy and Safety of a Selective Regulatory T-Cell-Inducing Interleukin-2 Conjugate (Rezpegaldesleukin) in the Treatment of Atopic Dermatitis: Final Results from a Randomized Phase 1b Study. Poster Presentation. European Academy of Dermatology and Venereology Annual Meeting, Berlin, Germany. October 11-14, 2023.
- Silverberg J, Chovatiya R, Rosmarin D, Beck L, Gooderham M, Blauvelt A, Schleicher S, Chaudhry S, Fanton C, Yu D, Liu Y, Lee Z, Marcondes M, Kotzin B, Tagliaferri M, Zalevsky J, Bieber T. A Phase 2b, Randomized, Double-Blinded, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in Adults with Moderate-to-Severe Atopic Dermatitis. Poster Presentation (Oral poster). European Academy of Dermatology and Venereology Annual Meeting, Berlin, Germany. October 11-14, 2023.
- Ingram J, Porter M, Chovatiya R, Giamarellos-Bourboulis EJ, Bechara FG, Fujita H, Gulliver W, Muller E, Bari M, Rolleri R, Byerly R, Kirby JS. Bimekizumab response maintenance to 48 weeks in patients with moderate to severe hidradenitis suppurativa: Pooled responder analysis from the phase 3, double-blind, placebo-controlled, randomised clinical trials BE HEARD I and II. Poster Presentation. European Academy of Dermatology and Venereology Annual Meeting, Berlin, Germany. October 11-14, 2023.
- Simpson E, Biedermann T, Kircik L, Chovatiya R, Figueras I, Casillas M, Gallo G, Ding Y, Xu C, Pierce P, Agell H, Vestergaard C. Raising the Bar of Efficacy in Atopic Dermatitis: Lebrikizumab Provides Sustained Deep Clinical and Itch Responses Up to 52 Weeks. Poster Presentation (Oral presentation). European Academy of Dermatology and Venereology Annual Meeting, Berlin, Germany. October 11-14, 2023.
- Alexis A, Hansen M, Casillas M, Rueda MJ, Becker TB, Chovatiya R. Paving the way to healthcare equity: Raising awareness of existing gaps in the dermatologic care of diverse populations in the United States. Poster Presentation. Skin of Color Update 2023, New York, NY.
- Prajapati VH, Simpson EL, Thyssen JP, Chovatiya R, Lane M, Teixeira HD, Calimlim BM, Silverberg JI. Absolute EASI target in moderate-to-severe atopic dermatitis: analysis of data from the measure up 1 and 2 studies. Associazione Dermatologi Ospedalieri Italiani - 60th Congresso Nazionale, Vicenza, Italy. September 27-30, 2023.
- Trzeciak M, Chovatiya R, Geng B, Biswas P, Güler E. Temporal Response Patterns of Abrocitinib and Dupilumab in Patients With Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of the JADE DARE Trial. Poster Presentation. International Society of Atopic Dermatitis Annual Meeting, Gdansk, Poland. August 3 – September 2, 2023.
- Simpson EL, Chovatiya R, Blauvelt A, de Bruin-Weller M, Praestgaard A, Shumel B, Rodriguez Marco A. Sequence of Improvement in Atopic Dermatitis Signs and Symptoms in Adults Treated With Dupilumab. Poster presentation. World Congress of Dermatology, Singapore, SG. July 3-8, 2023.
- Aldredge L, Reynolds M, Dawson Z, Marwaha S, Pansch LA, Cheever E, Chovatiya R, Malatestinic W, Anderson P, Pierce E, Atwater AR, Piercy J, Silverberg JI. Patients with moderate-to-severe atopic dermatitis experience heterogeneous disease course phenotypes: Results of a real-world study in the United States. Poster Presentation. Dermatology Essential Resource Meeting (DERM), Las Vegas, NV. August 3-6, 2023.
- Aldredge L, Reynolds M, Dawson Z, Marwaha S, Pansch LA, Cheever E, Chovatiya R, Malatestinic W, Anderson P, Pierce E, Atwater AR, Piercy J, Silverberg JI. Patients with moderate-to-severe atopic dermatitis experience heterogeneous disease course phenotypes: Results of a real-world study in the United States. Poster Presentation. Fall Clinical Dermatology Conference for NPs and PAs, Orlando, FL. June 9-11, 2023.
- Chovatiya R, Aldredge L, Heath C, Acevedo C, Chu DH, Hanna D, Seal M, Zirwas M. Patient and Healthcare Provider Perspectives on the Disease Burden of Seborrheic Dermatitis in the United States: Results from a National Survey. Poster Presentation. Fall Clinical Dermatology Conference for NPs and PAs, Orlando, FL. June 9-11, 2023.
- Fakhraie S, Chovatiya R. Social Media as an Educational Platform for Seborrheic Dermatitis. Oral presentation (Concurrent Mini-Symposium: Clinical Research – Sociobehavioral and Health Services Research). International Societies of Investigative Dermatology Meeting, Tokyo, Japan. May 10-13, 2023.
- Chovatiya R, Balu S, Kim Y, Althoff AG, Rasouliyan L. Early Insights into the Characteristics of Tralokinumab Patients in a Real-World Setting in the United States. Poster presentation, Revolutionizing Atopic Dermatitis Conference, Washington, D.C. April 29-May 1, 2023.
- Murase J, Chovatiya R, Strowd L, Thyssen J, Bangert C, Atwater A, Gallo G, Bardolet L, Yang F Zhong J, Staumont-Sallé D. Improved and Cleared Facial and Hand Dermatitis in Patients Treated With Lebrikizumab for Moderate-to-Severe Atopic Dermatitis. Oral presentation (Late-Breaking Research), Revolutionizing Atopic Dermatitis Conference, Washington, D.C. April 29-May 1, 2023.
- Fakhraie S, Daftary, K., Venkaesh, S, Chovatiya R. Lichen Amyloidosis: Toward Pathogenesis-Driven Targeted Treatment. Oral presentation (Gross and Microscopic Dermatology Symposium), American Academy of Dermatology Annual Meeting, New Orleans, LA, March 17, 2023.
- Chovatiya R, Aldredge L, Heath C, Acevedo C, Chu DH, Hanna D, Seal M, Zirwas M. Patients’ and Healthcare Providers’ Perspectives on the Path to Diagnosis and Educational Resources of Seborrheic Dermatitis in the United States: Results from a National Survey. J Am Acad Dermatol. 89(3):AB73. Oral presentation (Oral poster), American Academy of Dermatology Annual Meeting, New Orleans, LA. March 17, 2023.
- Chovatiya R, Aldredge L, Heath C, Acevedo C, Chu DH, Hanna D, Seal M, Zirwas M. Patient and Healthcare Provider Perspective on the Treatment Patterns and Patient Satisfaction of Seborrheic Dermatitis in the United States: Results from a National Survey. J Am Acad Dermatol. 2023 Sep;89(3):AB71. Oral presentation (Oral poster), American Academy of Dermatology Annual Meeting, New Orleans, LA. March 17, 2023.
- Chovatiya R, Aldredge L, Heath C, Acevedo C, Chu DH, Hanna D, Seal M, Zirwas M. Patient and Healthcare Provider Perspectives on the Disease Burden of Seborrheic Dermatitis in the United States: Results from a National Survey. J Am Acad Dermatol. 89(3):AB71. Oral presentation (Oral poster), American Academy of Dermatology Annual Meeting, New Orleans, LA. March 17, 2023.
- Kudlaty E, Chovatiya R. Dupilumab as Add-On Therapy for Management of Chronic Spontaneous Urticaria: A Single Center Retrospective Study. Oral presentation (Oral poster), American Academy of Dermatology Annual Meeting, New Orleans, LA. March 17, 2023.
- Brady K, Fakhraie S, Chovatiya R. Attitudes and Utilization of Complementary and Alternative Medicine in Dermatology: A Single Center Cross-Sectional Study. Oral presentation (Oral poster), American Academy of Dermatology Annual Meeting, New Orleans, LA. March 17, 2023.
- Fakhraie S, Erickson T, Chovatiya R. YouTube As a Source of Information about Seborrheic Dermatitis. Oral presentation (Oral poster), American Academy of Dermatology Annual Meeting, New Orleans, LA. March 17, 2023.
- Stefanko N, Quan V, Chovatiya R. Efficacy, Safety, and Treatment Patterns of Ruxolitinib 1.5% Cream in Adult Atopic Dermatitis: A Single Center Retrospective Study. Poster presentation, American Academy of Dermatology Annual Meeting, New Orleans, LA. March 17, 2023.
- Chovatiya R, Balu S, Kim Y, Althoff AG, Rasouliyan L. Early Insights into the Characteristics of Tralokinumab Patients in a Real-World Setting in the United States. Poster presentation, Winter Clinical Dermatology Conference – Miami, Miami, FL. February 17-20, 2023.
- Orenstein LAV, Rahawi K, Danavar A, Lane M, Chovatiya R, Lev-Tov H, Paek SY, Van der Zee HH, Sayed CJ. Burden of pain and use of pain medications in patients with HS: real-world data from UNITE. Poster presentation, 12thAnnual Conference of the European Hidradenitis Suppurativa Foundation (EHSF), Florence, IT. February 8-10, 2023.
- Silverberg JI, Thyssen JP, Lazariciu I, Valdez H, Myers DE, Guler E, Chovatiya R.Efficacy of abrocitinib and dupilumab in patients with atopic dermatitis characterized by severe itch and moderate or severe lesions: a pooled analysis of 2 randomized trials. Poster presentation, Maui Derm Hawaii, Maui, HI. January 23-27, 2023.
- Chovatiya R, Aldredge L, Heath C, Acevedo C, Chu DH, Hanna D, Seal M, Zirwas M. Patient and Healthcare Provider Perspectives on the Treatment Patterns and Patient Satisfaction of Seborrheic Dermatitis in the United States: Results from a National Survey. Poster presentation, Fall Clinical Dermatology Conference, Las Vegas, NV. October 20, 2022.
- Silverberg JI, Thyssen JP, Lazariciu I, Valdez H, Myers DE, Guler E, Chovatiya R.Efficacy of abrocitinib and dupilumab in patients with atopic dermatitis characterized by severe itch and moderate or severe lesions: a pooled analysis of 2 randomized trials. Poster presentation, International Society of Atopic Dermatitis Annual Meeting, Montreal, Canada. October 2022.
- Prajapati VH, Simpson EL, Thyssen JP, Chovatiya R, Lane M, Teixeira HD, Calimlim BM, Silverberg JI. Absolute EASI target in moderate-to-severe atopic dermatitis: analysis of data from the measure up 1 and 2 studies. International Society of Atopic Dermatitis Annual Meeting, Montreal, Canada. October 2022.
- Orenstein LAV, Rahawi K, Danavar A, Lane M, Chovatiya R, Lev-Tov H, Paek SY, Van der Zee HH, Sayed CJ. Burden of pain and use of pain medications in patients with HS: real-world data from UNITE. Oral presentation, Symposium on Hidradenitis Suppurativa Advances, Miami, FL. October 2022.
- Silverberg JI, Thyssen JP, Lazariciu I, Valdez H, Myers DE, Guler E, Chovatiya R. Abrocitinib improves itch and quality of life in patients with itch-dominant atopic dermatitis. Poster presentation, European Academy of Dermatology and Venereology Annual Meeting, Milan, Italy. September 2022.
- Simpson E, Chovatiya R, Schmid-Grendelmeier P, Lazariciu I, Myers DE, Clibborn C.. Multidomain Responses to Abrocitinib 100 mg With or Without Background Topical Medications in Adults with Atopic Dermatitis: A Post Hoc Analysis. Poster presentation, Skin of Color Update, New York, NY. September 2022.
- Alexis A, Chovatiya R, Davis L, Gomez B, Han G, Oh T. Efficacy of bimekizumab in patients with psoriasis and skin of color: Pooled data from four multicenter, double-blind, randomized phase 3 trials. Poster presentation, Skin of Color Update, New York, NY. September 2022.
- Han G, Chovatiya R, Davis L, Gomez B, Alexis A, Oh T, Beaty S. Patient-reported quality of life in patients with psoriasis with skin of color: Pooled data from four multicenter, double-blind, randomized phase 3 trials. Poster presentation, Skin of Color Update, New York, NY. September 2022.
- Chovatiya R, Begolka WS, Thibau IJ, Silverberg JI. The burden of atopic dermatitis out-of-pocket healthcare expenses in united states children. J Invest Dermatol. 142(8):S59. Oral presentation (Oral Poster), Society of Investigative Dermatology Annual Meeting, Portland, OR. May 2022.
- Chovatiya R, Schuttelaar ML, Calimlim B, Liu Y, Takemoto S, Ständer S. Achieving a Deep Response on Patient-Reported Outcomes with Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Results From Three Phase 3 Trials. Poster presentation, World Allergy Organization (WAO) and British Society for Allergy & Clinical Immunology (BSACI) Joint Conference, Edinburgh, Scotland. April 2022.
- Simpson E, Chovatiya R, Schmid-Grendelmeier P, Lazariciu I, Myers DE, Clibborn C.. Multidomain Responses to Abrocitinib 100 mg With or Without Background Topical Medications in Adults with Atopic Dermatitis: A Post Hoc Analysis. Br J Dermatol. 187(3):P189. Oral presentation (Late-Breaking Research), Revolutionizing Atopic Dermatitis Conference. April 9-11, 2022.
- Chovatiya R, Begolka WS, Thibau IJ, Silverberg JI. The burden of atopic dermatitis polypharmacy and out-of-pocket healthcare expenses in the United States. Br J Dermatol. 187(3):P189. Poster presentation, Revolutionizing Atopic Dermatitis Conference, Baltimore, MD. April 9-11, 2022.
- Chovatiya R, Pink AE, Jazayeri S, Ladizinski B, Calimlim BM, Davis J, Liu M, Bissonnette R. Economic impact of upadacitinib monotherapy and combination therapy for moderate to severe atopic dermatitis: 16-week work-productivity and activity-impairment results from Measure Up 1 and AD Up. Poster presentation, American Managed Care Pharmacy Annual Meeting, March 2022.
- Chovatiya R, Begolka WS, Thibau IJ, Silverberg JI. Atopic Dermatitis Polypharmacy and Out-Of-Pocket Healthcare Expenses in the United States. J Am Acad Dermatol. 87(3):AB21. Oral presentation (Oral Poster), American Academy of Dermatology Annual Meeting, Boston, MA. March 25-29, 2022.
- Chovatiya R, Fargnoli MC, King B, Shi V, Vestergaard C, Puig L, Biswas P, DiBonaventura M, Levenberg M, Clibborn C. Characteristics of the Efficacy Response Trajectory Among Patients Who Did Not Flare During the Maintenance Phase of JADE REGIMEN. J Am Acad Dermatol. 87(3):AB28. Oral presentation (Oral Poster), American Academy of Dermatology Annual Meeting, Boston, MA. March 25-29, 2022.
- Chovatiya R, Schuttelaar ML, Calimlim B, Liu Y, Takemoto S, Ständer S. Achieving a Deep Response on Patient-Reported Outcomes with Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Results From Three Phase 3 Trials. Br J Dermatol. 186(4):P638. Oral presentation (Late-Breaking Research), Revolutionizing Atopic Dermatitis Conference, Virtual Meeting, December 11-13, 2021.
- Silverberg JI, Gooderham MJ, de Bruin-Weller MS, Papp KA, Aoki V, Paller AS, Ofori S, Tenorio AR, Liu Y, Liu J, Chovatiya R. Characterization of Hematologic and Transaminase Laboratory Findings Associated With Upadacitinib Use in Moderate-to-Severe Atopic Dermatitis: Results of Two Phase 3 Trials (Measure Up 1 and 2). Br J Dermatol. 186(4):P638. Poster presentation, Revolutionizing Atopic Dermatitis Conference, Virtual Meeting December 11-13, 2021.
- Thyssen JP, Hong HC, de Bruin-Weller MS, Aschoff R, Armstrong AW, Chovatiya R, Vestergaard C, Rojo R, Valdez H, Zhang F, Bhambri A, Myers DE, Watson K, Guler E, Clibborn C, DiBonaventura M. Improvement in Patient-Reported Symptoms and Quality of Life With Abrocitinib Versus Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis Who Received Background Topical Therapy: Results of a 26-Week, Randomized, Head-to-Head Trial. Br J Dermatol. 186(4):P638. Poster presentation, Revolutionizing Atopic Dermatitis Conference, Virtual Meeting, December 11-13, 2021.
- Chovatiya R, Begolka WS, Thibau IJ, Silverberg JI. Financial Burden and Impact of Atopic Dermatitis Out-Of-Pocket Healthcare Expenses Among Black Individuals in the United States. Br J Dermatol. 185(3):P494. Oral presentation (Late-Breaking Research), Revolutionizing Atopic Dermatitis Conference, Virtual Meeting, June 13, 2021.
- Chovatiya R*, Begolka WS*, Thibau IJ, Silverberg JI. Impact and Associations of Atopic Dermatitis Out-Of-Pocket Healthcare Expenses in the United States. J Invest Dermatol. 141(5):S59. Oral presentation (Concurrent Mini-Symposium: Patient Population Research), Society of Investigative Dermatology Annual Meeting, Virtual Meeting, May 2021. *co-first authors
- Chovatiya R*, Begolka WS*, Thibau IJ, Silverberg JI. Financial Burden of Atopic Dermatitis Out-Of-Pocket Health Care Expenses in the United States. J Am Acad Dermatol. 85(3):AB31. Oral presentation (Oral Poster), American Academy of Dermatology Annual Meeting, Virtual Meeting Experience. April 2021. *co-first authors
- Chovatiya R, Silverberg JI. Itch Dominant Atopic Dermatitis: A Distinct Phenotype of Atopic Dermatitis. J Invest Dermatol. 140(7):S73. Poster presentation, Society of Investigative Dermatology Annual Meeting, Scottsdale, AZ (virtual due to COVID-19 pandemic), July 2020.
- Chovatiya R, Silverberg JI. Itch Dominant Atopic Dermatitis: A Distinct Phenotype of Atopic Dermatitis. Br J Dermatol. 184(4):P48. Poster presentation, Revolutionizing Atopic Dermatitis Conference, Chicago, IL (virtual due to COVID-19 pandemic), April 2020.
- Chovatiya R, Silverberg JI. Inpatient Morbidity and Mortality of Measles in the US. Poster presentation, Lewis Landsberg Research Day, Northwestern University Feinberg School of Medicine, Chicago, IL (cancelled due to COVID-19 pandemic), April 2020.
- Chovatiya R, Silverberg JI. Chronic Inflammatory Skin Diseases are Associated with Herpes Zoster in US Inpatients. J Am Acad Dermatol. 83(6):AB25. Oral presentation (Oral Poster), American Academy of Dermatology Annual Meeting, Denver, CO (virtual due to COVID-19 pandemic), March 2020.
- Chovatiya R, Brieva J. Malignant Angiosarcoma Masquerading as Benign Epithelioid Hemangioma. Oral presentation (Gross and Microscopic Dermatology Symposium), American Academy of Dermatology Annual Meeting, Denver, CO (virtual due to COVID-19 pandemic), March 2020.
- Chovatiya R, Silverberg, JI. Chronic Inflammatory Skin Diseases are Associated with Herpes Zoster in US Inpatients. Oral presentation (Resident of Distinction), Coastal Dermatology Symposium, Seattle, WA, October 2019.
- Chovatiya R, Silverberg, JI. Morbidity and Mortality of Measles in US Inpatients. J Invest Dermatol. 139(5):S41. Oral presentation (Concurrent Mini-Symposium: Epidemiology), Society of Investigative Dermatology Annual Meeting, Chicago, IL, May 2019.
- Chovatiya R, Silverberg JI. Association of Pemphigus and Bullous Pemphigoid with Osteoporosis and Fractures. Poster presentation, Lewis Landsberg Research Day, Northwestern University Feinberg School of Medicine, Chicago, IL, April 2019.
- Chovatiya R, Silverberg, JI. Inflammatory Skin Diseases are Associated Osteoporosis and Pathological Fractures. Oral presentation (Residents and Fellows Symposium), American Academy of Dermatology Annual Meeting, Washington, DC, March 2019.
- Chovatiya R, Silverberg, JI. Association of Pemphigus and Bullous Pemphigoid with Osteoporosis and Fractures. J Am Acad Dermatol. 81(4):AB24. Oral presentation (Oral Poster), American Academy of Dermatology Annual Meeting, Washington, DC, March 2019.
- Chovatiya R, Clarke, C. Vesicular Pityriasis Rosea. Oral presentation (Gross and Microscopic Dermatology Symposium), American Academy of Dermatology Annual Meeting, Washington, DC, March 2019.
- Chovatiya R, Silverberg JI. Inverse Association of Chronic Idiopathic/Spontaneous Urticaria with Osteoporosis and Fractures. J Allergy Clin Immunol. 143(2):AB49. Poster presentation, American Academy of Allergy, Asthma, and Immunology Annual Meeting, San Francisco, CA, February 2019.
- Chovatiya R, Choi, JN. Carcinoma Erysipeloides. Oral presentation (Case Presentation), Chicago Dermatologic Society Meeting, Chicago, IL, November 2018.
- Chovatiya R, Silverberg, JI. Association of Pemphigus and Bullous Pemphigoid with Osteoporosis and Fractures. SKIN J Cutan Med. 2:S97-S98. Oral presentation (Rising Derm Stars Symposium), Fall Clinical Dermatology Conference, Las Vegas, NV, October 2018.
- Chovatiya R, Mancini, AJ. Lipoatrophic Panniculitis. Oral presentation (Case Presentation), Chicago Dermatologic Society Meeting, Chicago, IL, November 2017.
- Chovatiya R, Medzhitov, R. Identification of a Stress-Induced Parainflammatory Signal in Mammalian Cells. Poster presentation, Student Research Day, Yale University School of Medicine, New Haven, CT, May 2016.
- Chovatiya R, Brodsky, JL. “Molecular Modulators of Hsp70: A Novel Attack on Cancer.” Oral presentation, Tenth Annual Arnold and Mabel Beckman Scholars Symposium, Irvine, CA. July 2008.
- Chovatiya R, Wright CM, Jameson NE, Turner DM, Zhu G, Werner S, Pipas JM, Day DW, Wipf P, Brodsky JL. Pyrimidinone-Peptoid Hybrid Molecules with Distinct Effects on Molecular Chaperone Function and Cancer Cell Proliferation. Poster presentation, Midwest Stress Response and Chaperone Annual Meeting, Evanston, IL, January 2008.